Completed PHASE3 INTERVENTIONAL 2-arm NCT01179672

A Study in Participants With Diabetic Peripheral Neuropathic Pain in China

Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo

Sponsor: Eli Lilly and Company

Updated 7 times since 2017 Last updated: Oct 3, 2014 Started: Apr 30, 2011 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetic Neuropathy, Painful and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Changchun, China , Chengdu, China , Chongqing, China , Guangzhou, China , Jinan, China , Nanjin, China , Qingdao, China , Shanghai, China and 5 more locations